All In Biotech

Drug Trial Radar · NCT04591431

The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy

Last checked: Nov 19, 2026Latest source record: Oct 3, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 400 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

400

Actual

Start

Oct 7, 2020

Primary completion

Dec 2024

Study completion Jun 2025

Sponsor

Lead sponsor
Fondazione per la Medicina PersonalizzataAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 19, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, prospective, multicenter, Proof of Concept, Phase II clinical trial Study. The main objective of the study is to evaluate the efficacy (meant as overall response rate ORR) of TT (targeted Therapy) vs SoC (standard of Care) in patients with progressive disease (recurrent and/or metastatic) of breast cancer, metastatic gastro-intestinal tumors, non small cell lung cancer (NSCLC) or others. Patients should have completed at least 1 line of treatment and no more than 2 as defined by the current version of the AIOM (Italian Association of Medical Oncology) guidelines. Patients are included if surgery is contraindicated.

Conditions

  • Breast Cancer
  • Gastrointestinal Cancer
  • Non Small Cell Lung Cancer
  • Other Cancer

Interventions

  • ErlotinibDrug

    TT arm

  • TrastuzumabDrug

    TT arm

  • Trastuzumab emtansineDrug

    TT arm

  • PertuzumabDrug

    TT arm

  • LapatinibDrug

    TT arm

  • EverolimusDrug

    TT arm

  • VemurafenibDrug

    TT arm

  • CobimetinibDrug

    TT arm

  • AlectinibDrug

    TT arm

  • BrigatinibDrug

    TT arm

  • PalbociclibDrug

    TT arm

  • PonatinibDrug

    TT arm

  • VismogedibDrug

    TT arm

  • ItacitinibDrug

    TT arm

  • IpatasertibDrug

    TT arm

  • EntrectinibDrug

    TT arm

  • AtezolizumabDrug

    TT arm

  • NivolumabDrug

    TT arm

  • IpilimumabDrug

    TT arm

  • PemigatinibDrug

    TT arm

  • Oncology DrugsDrug

    Standard of Care Arm

  • PralsetinibDrug

    TT arm

  • SelpercatinibDrug

    TT arm

  • TalazoparibDrug

    TT arm

  • TepotinibDrug

    TT arm

  • AlpelisibDrug

    TT arm

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. OVERALL RESPONSE RATE (ORR)Time frame: 42 months

Locations

37 sites in 1 country. Site status is shown where the registry gives one.

  • OSPEDALI RIUNITI di ANCONA

    Ancona, Italy

  • Centro Riferimento Oncologico

    Aviano, Italy

  • Irccs Oncologico Istituto Tumori Giovanni Paolo Ii - Bari

    Bari, Italy

  • Asst Papa Giovanni Xxiii

    Bergamo, Italy

  • Ospedale Bellaria

    Bologna, Italy

  • Ospedale di Carpi

    Carpi, Italy

  • Arnas Garibaldi- Nuovo Ospedale Garibaldi - Nesima

    Catania, Italy

  • A.O. Mater Domini Catanzaro

    Catanzaro, Italy

  • Azienda Ospedaliero-Universitaria Di Ferrara

    Ferrara, Italy

  • E.O. Ospedali Galliera

    Genova, Italy

  • Ospedale Policlinico San Martino

    Genova, Italy

  • Ospedale Della Misericordia

    Grosseto, Italy

  • I.R.S.T. Srl Irccs

    Meldola, Italy

  • Ao Papardo

    Messina, Italy

  • Istituto Europeo Di Oncologia

    Milan, Italy

  • Istituto Nazionale Tumori Di Napoli Irccs Pascale

    Naples, Italy

  • Ospedale Classificato Sacro Cuore - Don Calabria

    Negrar, Italy

  • I.R.C.C.S. Istituto Oncologico Veneto

    Padova, Italy

  • Az.Osp.Univ.P.Giaccone

    Palermo, Italy

  • Azienda Ospedaliera Di Perugia

    Perugia, Italy

  • Casa Di Cura Privata Osp. P. Pederzoli

    Peschiera del Garda, Italy

  • Azienda Usl Di Piacenza

    Piacenza, Italy

  • Azienda Ospedaliero-Universitaria Pisana

    Pisa, Italy

  • Nuovo Ospedale Di Prato - S. Stefano

    Prato, Italy

  • Ospedale "Santa Maria Delle Croci"

    Ravenna, Italy

  • Arcispedale Santa Maria Nuova Di Reggio Emilia

    Reggio Emilia, Italy

  • Az. Osp. Uni. Policlinico Umberto I

    Roma, Italy

  • Azienda Ospedaliera Sant'Andrea

    Roma, Italy

  • Istituti Fisioterapici Ospitalieri- Ifo - Istituto Regina Elena

    Roma, Italy

  • Ospedale Fatebenefratelli

    Roma, Italy

  • Policl. Univ. Campus Bio Medico

    Roma, Italy

  • Casa Sollievo della Sofferenza - Opera Padre Pio

    San Giovanni Rotondo, Italy

  • Azienda Ospedaliera 'S. Maria' - Terni

    Terni, Italy

  • AO Ordine Mauriziano

    Torino, Italy

  • Humanitas Gradenigo

    Torino, Italy

  • IRCCS Candiolo

    Torino, Italy

  • Complesso Ospedaliero Di Belcolle- Ospedale Di Belcolle

    Viterbo, Italy

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.